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Abstract 
 
Endocrine signaling via nuclear receptors (NRs) is known to play an important role in normal 
physiology as well as in human tumor progression. Hormones regulate gene expression by 
altering local chromatin structure and, thereby, accessibility of transcriptional co-regulators to 
DNA. Recently it has been shown that non-histone proteins involved in hormone signaling, 
such as nuclear receptors and NR co-activators, are regulated by acetylation, resulting in 
their altered transcriptional activity. NAD-dependent protein deacetylases, the sirtuins (Sir2-
related enzymes), directly modify NRs. Because sirtuins have been shown to regulate tumor 
cellular growth, aging, metabolic signaling and endocrine hormone signaling, they might play 
a role in cancer progression. This review focuses on the role of acetylation and the sirtuins in 
nuclear hormone receptor signaling.  
 
 
Introduction 
 
Histone modification  
 
In eukaryotes, genomic DNA is packaged by histones and non-histone proteins into 
chromatin, which is further organized as repeating units of nucleosomes. The nucleosome 
consists of 147 base pairs of DNA wrapped around a protein core of histones (an H3–H4 
tetramer and two H2A–H2b dimers) [5]. Histone proteins consist of a globular domain and a 
more flexible charged N-terminus, known as the histone tail. Covalent modifications of the 
histone tail include acetylation, phosphorylation, methylation and ubiquitination. Such 
modification of chromatin structure is evident during cell-cycle progression, DNA replication, 
DNA damage and repair, recombination and overall chromosome stability [5].In addition, 
alteration to histones and non-histone proteins by acetylation plays a role in transcriptional 
activation and DNA-binding affinity, protein stability, protein–protein interactions, protein 
transport within the cell and nucleus, and activity of molecular chaperone proteins [6].  
 
The acetylation status of histone proteins alters gene transcription. Removal of acetyl groups 
from lysine residues results in compaction of chromatin and, hence, repression of gene 
transcription [6]. As such, transcriptionally active euchromatin is typically hyperacetylated, 
compared with inactive heterochromatin which tends to be hypoacetylated [7].Inaddition, the 
N-terminal modification of histone tails provides recognition sites for factors involved in gene 
transcription. Acetylation of lysine residues provides a recognition motif for bromodomains. 
Other post-translational modifications of histones serve to recruit additional proteins with 
enzymatic activity and/or tethering functions for other proteins: methylation is recognized by 
chromo-like domains of the Royal family and phosphorylation is recognized by 14–3-3 
proteins. Methylated histones (e.g. H3K4-Me3) recognize the PDH domain contained within 
BPTF, which recruits the NURF complex.  
Post-translational modification of histones, in turn, can modify subsequent access of other 
enzymes. Distinct modifications of lysines are mutually exclusive. Binding of proteins might 
be excluded or enhanced by such modifications, and a catalytic activity of an enzyme can be 
modified by local enzymatic changes. For example, the phosphorylation of H3S10 regulates 
the binding of HP1 to methylated H3K9. Furthermore, isomerization of H3P38 governs 
methylation of H3K36 by Set 2. The prevailing evidence suggests that signal transduction 
pathways might coordinate sequential and carefully orchestrated post-translational 
modification of histones with distinct enzymatic activity. Although historically the notion of a 
histone code was used to describe the role of modifications in governing DNA functions, an 
expanded view considers the post-translational modification of histones to encode precise 
information governing gene expression. The hypothesis of the ‘histone code’ was initially 
proposed to be responsible for extending the information potential of genetic material within a 
cell [5].  
 
Multiple proteins with acetyl transferase activity have been identified, and they are most 
commonly referred to as histone acetyl transferases (HATs).  HATs are classified on the 
basis of their subcellular location: type A HATs are usually localized in the nucleus, whereas 
type B can be found in the cytoplasm. Type A HATs are involved in transcriptional regulation 
through their acetylation of nucleosomal histones within local chromatin. However, within the 
cytoplasm, type B HATs are thought to possess a ‘house-keeping’ role, acetylating newly 
formed free histones. Alterations in expression, translocation, amplification or mutationof 
genes encodingHATshave been found in several cancers [6]. One example is the breast-
cancer susceptibilitygene BRCA2,which exhibits acetyltransferase activity [8].  
The histone deacetylases (HDACs) have been divided into four groups based on their 
similarity to yeast transcriptional repressors. Class I and II HDACs are similar to the yeast 
Rpd3p and Hda1p proteins. Class III HDACs share similarity to the yeast transcriptional 
repressor Sir2p and are referred to as sirtuins. Class I and II HDACs are characterized by 
their sensitivity to inhibition by trichostatin A (TSA), whereas class III HDACs are nicotinamide 
adenine dinucleotide (NAD)-dependent. A fourth class includes the deacetylase HDAC11 [9]. 
This review will concentrate on the class III HDACs, the sirtuins.  
Nuclear receptor modification by acetylation  
 
Since the identification of p53 as a non-histone target of HATs, a growing body of evidence 
has shown an important role for acetylation and deacetylation of non-histone proteins in 
cellular physiology [10]. Several transcription factors, including the nuclear hormone 
receptors (estrogen receptor α (ERα), androgen receptor (AR), thyroid hormone receptor β 
(TRβ) and glucocorticoid receptor (GR)), p53 [11,12], GATA-1 [13], GATA-2 [14], GATA-3 
[15], EKLF [16] and HMG proteins [17], are altered by acetylation. Acetylation of transcription 
factors results in altered binding to DNA, transcriptional activation, protein stability, 
subcellular localization and altered protein–protein interactions. For example, the tumor 
suppressor p53 is acetylated by p300, which functions as a rate-limiting cointegrator in 
diverse nuclear receptor signaling pathways, within its C-terminal domain, resulting in 
sequence-specific DNA binding [11] both in vitro and in vivo [12]. Recent studies have 
demonstrated that the individual acetylation sites of p53 determine its DNA binding [18]. 
Differential acetylation at distinct acetylation sites results in altered downstream effects, 
including cell survival after DNA damage, interaction with co-repressors and co-activators, 
interaction with downstream promoters, nuclear retention and DNA binding.  
 
The AR plays a crucial role in prostate cancer proliferation as androgens induce proliferation 
and inhibit apoptosis. Androgen ablation therapy remains an important therapeutic in the 
management of metastatic prostate cancer. Hyperactivity of the AR is associated with loss of 
responsiveness to androgen therapy and androgen-insensitive prostate cancer (AIPC). Post-
translational modification of the AR, including hyperacetylation, probably contributes to this 
hyperactivation. Acetylation of the AR by HATs (e.g. CBP and p300) regulates ligand binding 
and alters the affinity of the AR for co-regulators. Acetylation of the AR might thereby regulate 
prostate cancer growth and cell death [19].  
 
The AR was the first nuclear receptor that was shown to be directly acetylated [20]. The 
residues of the AR that are acetylated in vitro by p300 are conserved among species and with 
other nuclear receptors [21]. Point mutation of the AR acetylation site to create acetylation 
mimic mutants enhanced ligand-dependent transactivation [20]. By contrast, acetylation dead 
mutants of the AR abrogated ligand-dependent transactivation. Although several functions 
are regulated by acetylation, including transactivation and contact-independent growth, the 
transrepression cAMP-and Akt-regulated function of the AR remained unaffected [22].  
 
In vivo, acetylation of the AR is enhanced by agonists such as bombesin and its ligand 
dihydrotestosterone [23]. The physiological function of the acetylation site of the androgen 
receptor includes regulation of cellular growth [24].The introduction of AR acetylation mimic 
mutants into human prostate cancer cells promoted the growth of cells both in vitro and in 
vivo. This enhanced cellular growth was a function of both enhanced cellular proliferation and 
reduced cellular apoptosis. This finding was of importance because it was the first study to 
demonstrate that acetylation of a transcription factor directly regulated contact-independent 
growth. The molecular mechanisms and genetic targets regulating the cell survival and 
proliferation phenotype remain to be characterized completely.  
 
It was previously shown that the AR can induce apoptosis. Substitution mutations of the AR 
acetylation sites abrogated tumor necrosis factor-α (TNF-α) and trail-induced apoptosis of 
human prostate cancer cells in culture. AR activity is induced by mitogen-activated protein 
kinase (MAPK) kinase kinase, which induces MKK4, Jun N-terminal kinase (JNK) and IκB 
kinases. MEKK1 induces prostate cancer cell apoptosis in an AR-dependent manner through 
JNK. Co-expression of MEKK1 and the wildtype AR in the presence of dihydrotestosterone 
induced apoptosis. Mutation of the AR acetylation site abrogated MEKK1-induced apoptosis. 
Collectively, these studies demonstrate that MEKK1 (Jun-kinase kinase)-dependent cellular 
apoptosis involves the AR acetylation site. In addition, AR acetylation site mimic mutants 
were resistant to MEKK1-dependent apoptosis [25].  
 
Prostate cancer cells transduced with acetylation mimic mutants of the AR showed enhanced 
cellular proliferation and induction of Ki67 [24]. These cells exhibited increased expression of 
proliferative cell-cycle markers including cyclin D1. Chromatin immunoprecipitation assays 
demonstrated enhanced recruitment of the gain-of-function AR acetylation site mutants to the 
cyclin D1 promoter [24]. Biochemical analysis of the molecular mechanisms by which the AR 
acetylation site regulates gene transcription indicated that lysines 630, 632 and 633 play a 
key role in the recruitment of the co-activator protein p300 and the disengagement of co-
repressor complexes including NCoR, HDAC1 and Smad3 [25]. In vitro analysis 
demonstrated the importance of these lysine residues in serving as docking sites for p300 
[25,26] (Figure1).  
Signaling cascades in transcription factors  
 
Studies of histones have demonstrated the interplay among post-translational modifications. 
For example prior modification of histones by phosphorylation regulates subsequent 
acetylation. The identification of post-translational modification of transcription factors raised 
the possibility that, like histones, one post-translational modification (i.e. phosphorylation) of 
transcription factors might regulate subsequent modification (i.e. acetylation or methylation). 
This hypothesis indicates that sequential post-translational modifications of transcription 
factors by phosphorylation, acetylation and ubiquitination might determine the signaling 
specificity of a transcription factor. The model in which these sequential post-translational 
modifications occur within transcription factors has been called signaling cascades in 
transcription factors (SCITs).  
 
Consistent with this model, the AR is modified by both acetylation and phosphorylation, and 
AR acetylation affects phosphorylation-dependent signaling. MAPK pathways activate the 
AR, and the AR is phosphorylated by several distinct signaling cascades. In view of previous 
studies suggesting that H3 phosphorylation and acetylation might be linked events [27], we 
investigated the role of the AR acetylation site in signaling by the key kinases implicated in 
AR signaling, MAPK, Akt and protein kinase A (PKA). Mutation of the AR acetylation site did 
not affect MAPK signaling [22]. The AR acetylation site mutants were, however, defective in 
regulation by HDAC inhibitors, Akt signaling and cAMP signaling. cAMP signaling normally 
regulates recruitment of the AR to an androgen response element in chromatin 
immunoprecipitation assays; however, this recruitment was abolished by AR acetylation site 
mutation [22]. Furthermore, the AR normally forms three molecular weight forms dependent 
upon phosphorylation.  Mutation of the AR acetylation site abrogated formation of the 114kDa 
phosphorylated form. The cAMP pathway, once activated, results in rapid dephosphorylation 
of the AR, in part through the induction of PKA-induced phosphatases. Collectively, this 
analysis of the inter-relationship between phosphorylation and acetylation of the AR has 
shown that AR acetylation regulates cAMP and Akt, but not MAPK-dependent,signaling of the 
AR [22](Figure2).These studies are consistent with prior analysis in which MAPK signaling to 
the ERa was unaffected by mutations in the ERa acetylation site [21].  
 
Chromatin access of the nuclear receptors (NRs) is regulated by the acetylation of local 
histones and histone demethylases. Point mutation of the six distinct AR phosphorylation 
sites led to the identification of a single site capable of regulating HDAC responsiveness [22].  
Chromatin immunoprecipitation assays demonstrated enhanced AR recruitment in the 
context of local chromatin, upon addition of HDAC inhibitors, or through treatment with DHT. 
Acetylation dead AR mutants were defective in both ligand- and HDAC-dependent 
recruitment to the endogenous PSA promoter [22]. These studies suggest that the acetylation 
status of the nuclear receptor itself regulates access to local chromatin. The model in which 
local enzymatic activity of HDACs regulates AR occupancy is consistent with a growing body 
of evidence that multiple distinct nuclear receptor modifying enzymes co-occupy AR-binding 
sites in the context of local chromatin (Figure 3). For example, histone demethylases have 
been shown to co-occupy nuclear hormone receptor sites, performing a gatekeeper function 
of preventing the occupancy of unliganded nuclear receptors into the context of local 
chromatin [28]. Many studies have dissected the components of the AR co-repressor and co-
activator complexes (reviewed in Ref. [29]).  
 
In addition to the AR, it has been demonstrated that several other nuclear receptors are 
acetylated. The ERa was initially shown to be acetylated by p300 at the same motif as the AR 
[21]. Mutational analysis identified a minimal region sufficient for acetylation and an ERα 
peptide encoding the site served as substrate for p300 HAT activity with similar properties to 
H3. Proteomic analysis demonstrated that Lys302 and Lys303 are preferential sites for 
acetylation. Independent clinical study identified Lys K303 as a site of frequent mutation in 
breast cancer [30]. Like p53, in which multiple distinct acetylation sites have been identified 
[18], additional acetylated ERα Lys residues were identified recently (K266/2681) in assays 
combining SRC1 with p300.  
 
The regulation of glucocorticoid receptor activity by acetylation is complex. HDAC6 regulates 
HSP90-dependent GR maturation [31]. The GR is acetylated after ligand binding. 
Mutagenesis of the acetylated residues (K494/ 495) reduced GR acetylation and GR-
mediated repression of nuclear factor-kB (NFkB) activity [32]. The addition of thyroxine 
results in the accumulation of acetylated TRb within 30 to 45 min. Inhibition of MAPK activity 
reduced thyroxine-induced TRb acetylation [33].  
 
In addition to the nuclear receptors and histones, several other components of the nuclear 
receptor signaling cascades are substrates for acetylation. For example, kinases (MEK2 and 
IKKa) and nuclear receptor co-regulators (p300, MTA1, PGC1a ACTR, and HDACs) also 
serve as substrates for acetylation by HATs. Collectively, these studies indicate an important 
link between the acetylation of non-histone proteins and nuclear hormone receptor signaling 
(Figure 3).  
 
Sirtuins: Sirt1 and the nuclear sirtuins  
 
The sirtuin family is a group of nicotinamide (NAD+)-dependent deacetylases that are 
conserved from archaeobacteria to eukaryotes [4,34]. The sirtuins were originally classified 
as type III HDACs, because histones were the first identified substrates of the yeast Sir2p 
gene [35]. Sir2 conveys NAD+-dependent ADP-ribosyltransferase activity, that is, the 
enzymatic activity of sirtuins is regulated by NAD
+
. In mammals, there are seven homologues 
of the yeast Sir2 gene, SIRT1–SIRT7, each with significant diver sity in function (Table 1). 
Mammalian sirtuins can be localized to the nucleus, cytoplasm or mitochondria, with distinct 
substrates and a broad range of functions [2]. The structure of the sirtuins includes a 
conserved core domain, with all seven homologues differing in their N-or C- terminal 
sequences [35]. SIRT1 is the human homolog of the yeast silent information regulator 2 (Sir2) 
gene.  Endogenous levels of nicotinamide probably limit Sirt1 activity, while the mechanisms 
regulating Sir2 activity might be regulated by either altered ratios of cellular NAD
+
:NADH [36] 
or free nicotinamide, and free NAD
+ 
levels might suppress Sir2 activity [37].  
 
The three nuclear sirtuins (SIRT1, SIRT6, and SIRT7) have distinct functions. SIRT1 is 
known to deacetylate more than ten substrates, including the nuclear receptors (AR, ERα), 
the NR co-activators (PGC1α, p300) [38–40], Ku70 and several transcription factors that are 
regulated by p300 (NFκB, FKHR). SIRT6 has weak deacetylase activity but significant auto-
ADP-ribosyltransferase activity. In an outbred background, SIRT6-/- mice develop defective 
skeletal fusion, osteoporosis, low insulin-like growth factor1 (IGF-1) levels, and hypoglycemia. 
Genomic instability in these mice is associated with enhanced sensitivity to DNA damaging 
agents and defective base excision repair. SIRT7 exhibits a nucleolar distribution within 
proliferating, but not quiescent, cells. This sirtuin lacks NAD
+
-dependent deacetylase activity 
and interacts with RNA polymerase I. An NAD
+
-binding motif in SIRT7 indicates that this 
family member might function to sense NAD
+ 
concentrations in proliferating cells and thereby 
regulates RNA Pol I activity.  
 
Cytosolic SIRT2 binds and deacetylates α-tubulin and histones, while preferentially 
deacetylating H4K16 [41]. Expression of SIRT2 is reduced in some cancers [42] and is 
increased during mitosis co-localizing with chromatin during the G2M phase [43]. SIRT2 
deacetylation of cytoskeletal proteins might regulate migration and/or their intracellular cargo 
in response to altered intracellular metabolism.  
The extended sirtuin family  
 
The mitochondrial sirtuins (SIRT3, SIRT4 and SIRT5) appear to regulate mitochondrial 
respiratory function. Both SIRT3 and SIRT4 are imported into the mitochondrial matrix 
[44,45]. SIRT3 is required for expression of the uncoupling protein 1 (UCP-1) [46]. SIRT3 
deacetylates and activates acetyl-coenzyme-A synthetase (AceSC2) [44, 47], thereby 
facilitating the entry of acetate into the tricarboxylic acid (TCA) cycle. Polymorphisms of 
SIRT3 have been linked to longevity [48,49]. SIRT4 ADP-ribosylates mitochondrial glutamate 
dehydrogenase, and subsequently inhibits its activity and blocks the conversion of glutamate 
to α -ketoglutarate. The cellular interactions and biological significance of SIRT5 are not yet 
known, although its structure suggests a deacetylase function.  
Sirtuins and nuclear receptors  
 
In addition to the TSA-sensitive histone deacetylases, NAD-dependent histone deacetylases 
(the sirtuins) regulate histone and non-histone protein structure and function and are 
important for nuclear hormone receptor signaling. One non-histone protein that is 
deacetylated by a sirtuin, Sirt1, is the co-activator p300 [39]. Sirt1 represses p300 in a NAD+-
dependent manner. The p300 HAT contains multiple distinct domains, including the cell cycle 
regulatory domain (CRD1), and lysine residues within the CRD1 domain are required for Sirt1 
repression of p300. The Lys residues within p300 function as substrates for Sirt1-mediated 
deacetylation, as well as for sumoylation. Additionally, the SUMO-specific protease, SSP3, 
antagonizes Sirt1-mediated repression of p300 [39]. Collectively, these studies demonstrate a 
key role for Sirt1 in regulating p300 deacetylation. Sirt1 regulation of p300 might thereby 
integrate metabolic signals within the cell, because diverse nuclear receptors are regulated 
by p300.  
 
In view of the key role for the AR acetylation site in regulating prostate tumor cellular growth 
in vivo, together with evidence that the incidence of prostate cancer increases with aging and 
the finding that the sirtuins might play a role in organismal aging, the potential role of the 
sirtuins in regulating AR function has been investigated. The AR has been shown to be 
repressed by SIRT1 in prostate epithelial cells. Consistent with this, confocal microscopy 
revealed co-localization of the AR and SIRT1 in a nuclear subcompartment [38]. SIRT1 
inhibited cellular proliferation in AR-expressing prostate cancer cell lines but not in cells that 
do not express AR [38], demonstrating that their interaction is physiologically relevant. 
Inhibition of SIRT1 with antagonists increased androgen-regulated gene transcription. 
Importantly, inhibitors of endogenous Sirt1 (Sirtinol, splitomycin and nicotinamide) induced 
endogenous AR gene expression. The repression of AR activity by Sirt1 required the catalytic 
function of Sirt1. The AR lysine residues that are acetylatedbyp300 serve as substrates for 
Sirt1-mediated deacetylation (Figure3). The ability of SIRT1 to deacetylate the AR and 
repress its activity might provide a novel and effective cancer therapy.  
 
What might be the physiological significance of the finding that Sirt1 inhibits AR activity? This 
model is consistent with a known role of androgens in maintaining muscle mass and in the 
induction of genes associated with muscle development. The AR is known to play a key role 
in several biological functions. In addition to maintaining muscle mass and reducing fat mass, 
the AR governs the pathological state driving tumors and the progression of prostate cancer. 
The metabolic changes induced by pyruvate increase the NAD
+
:NADH ratio in muscle cells 
thereby inhibiting muscle gene expression. Conversely the induction of lactate, which would 
reduce NAD
+
, might stimulate muscle gene expression [50].  
 
In the case of prostate cancer, recent studies have demonstrated that global changes in 
histone acetylation occur, in particular acetylation of H3K18, H4K12 and H3K9 [51]. These 
changes in acetylation are thought to be predictive of prostate cancer recurrence [51]. The 
role of Sirt1 in altering histone acetylation during prostate cancer progression and/or through 
AR function is currently unknown. However, it is known that during prostate cancer 
progression, cells shift towards cytosolic glycolysis [52]. The induction of lactate that occurs 
during prostate cancer progression [53] might be anticipated to inhibit Sirt1 and thereby 
enhance AR function [38].In prostate cancer cells, Sirtinol, a noncompetitive inhibitor of Sirt1, 
induced expression of the endogenous AR gene, as did the selective chemical Sirt1 inhibitor, 
splitomycin [38]. Therefore, it is proposed that Sirt1 might inhibit prostate cancer cellular 
growth by inhibiting AR function.  
 
Subsequent studies have demonstrated that other nuclear receptors, including the ERα, TRβ 
and GR, contain a functional conserved acetylation motif. The role of sirtuins in regulating 
these receptors is not known at this time; however, there is indirect evidence for the 
regulation of ERα by sirtuins. The ERα is acetylated by p300 at lysine residues within its 
hinge and ligand-binding domains [54]. These lysine residues are well conserved between 
species and with other nuclear receptors. Resveratrol was thought to function as a specific 
SIRT1 activator [55] and is an agonist for the ER [56]. However, resveratrol has diverse 
biological effects [57], including antioxidant properties, inhibition of mitochondrial ATPases 
and competition with co-enzyme Q, and this has led to the substrate specificity of resveratrol 
being called into question. Resveratrol was shown to enhance binding and deacetylation of 
peptide substrates that contain fluorophore (Fluor de Lys), a non-physiological fluorescent 
moeity, but not a similar acetylated peptide without a fluorophore. Resveratrol did not exert 
detectable effects on Sir2 activity (transcriptional silencing near telomeres, rDNA silencing) 
[58,59]. 
 
Resveratrol has chemopreventative properties [60], such as inhibiting preneoplastic 
mammary gland lesions [60]. The role of resveratrol in breast cancer cellular proliferation 
remains controversial [61,62].Inthe estrogen-dependent breast cancer cell line T47D, 
resveratrol promoted cell proliferation [56], whereas Mgbonyebi et al. [63] showed an anti-
proliferative effect of resveratrol in both ER-positive and ER-negative breast cancer cells. It 
has been reported that resveratrol has estrogenic and anti-estrogenic properties. A prevailing 
view is that resveratrol is a selective estrogen receptor modulator (SERM) that functions as 
an ER agonist in some tissues and as an ER antagonist in others. Further clarificationis 
necessary to determine whether resveratrol functions through SIRT to regulate ERα activity 
and whether this agent will have a clinical benefit in women diagnosed with breast cancer.  
 
Sirtuins and metabolism  
 
The sirtuin-dependent regulation of nuclear receptor coactivators has been linked to the 
regulation of glucose metabolism. Calorie restriction promotes insulin sensitivity and 
subsequent reductions in blood glucose and insulin levels [64]. Recent studies have linked 
Sirt1 to the nuclear receptor co-regulator PGC1a. SIRT1 regulates hepatic gluconeogenesis 
by promoting increased gluconeogenesis and by repressing glycolytic gene function. Through 
deacetylation of PGC1-a, SIRT1 enhances gluconeogenic gene transcription via interactions 
with hepatocyte nuclear factor 4a [40] associated with repression of glycolytic genes. SIRT1 
regulation of FOXO1 activity in hepatocytes has also been shown to enhance 
gluconeogenesis and glucose release [65].In addition, SIRT1 regulates insulin secretion in 
pancreatic b-cells [66,67]. These two groups have demonstrated that this mechanism is 
dependent on SIRT1-mediated repression of the uncoupling protein 2(UCP2) gene.  
 
A growing body of evidence has suggested a role for estrogen and estradiol-dependent gene 
transcription in regulating double-stranded DNA break repair [68].In this regard addition of 
estradiol induces transient double-stranded DNA breaks to which procyclic acidic repetitive 
protein (PARP) is recruited. Recent findings suggest a role for sirtuins in double-stranded 
DNA break repair. SIRT6 is predominantly a nuclear protein, with high levels of expression in 
mouse muscle, brain and heart [69]. Recent evidence points to a role for SIRT6 in resistance 
to DNA damage and suppression of genomic instability [70]. SIRT6-/- mice die within four 
weeks of birth after developing abnormalities that include loss of subcutaneous fat, 
lordokyphosis and severe metabolic defects [70]. Furthermore, MEFs deficient in SIRT6 show 
impaired proliferation and increased sensitivity to DNA damaging agents [70]. Haigis and 
Guarente [2] propose that SIRT6 can ADP-ribosylate substrate proteins involved in the base 
excision repair pathway, a mechanism by which SIRT6 could be regulating DNA damage 
repair [70].  
 
At this time the role of nuclear receptors in aging and their relationship to the function of 
sirtuins in aging is unknown. Restriction of calorie intake extends lifespan in several 
organisms, including yeast, flies, spiders, worms and rodents [2]. On the basis of the 
observation that Sir2 extension of lifespan in Caenorhabditis elegans involves the forkhead 
protein, Dauer formation 16 (DAF-16), a model has been proposed in which caloric restriction 
prolongs life through Sir2 signaling in conjunction with the DAF-2 insulin-like signaling 
pathway. SIRT1 expression is induced by calorie restriction and fasting, suggesting a role for 
SIRT1 in the regulation of fasting responses. Increased dosages of Sir2 homologues are also 
capable of increasing lifespan [71]. It has been proposed that Sir2 promotes longevity in 
yeast cells by reducing recombination of rDNA (rDNA) and the subsequent formation of 
extrachromosomal rDNA circles (ERCs). Strains deficient in SIR2 and NPT1 do not show an 
extension in lifespan [72], thereby emphasizing the importance of NAD+-activated Sir2p in 
prolonging life.  
Conclusion  
 
At least eight distinct types of post-translational modification of histones have been described. 
Several of the enzymes responsible for these modifications directly modify nuclear receptors. 
Acetylation, like phosphorylation, is now known to govern cellular growth [24]. The addition of 
ligand to nuclear receptors induces receptor acetylation [23]. Nuclear receptors contain intra-
receptor signaling modules consisting of cascades of phosphorylation, acetylation, 
ubiquitination and perhaps sumoylation [73]. Histone-modifying enzymes, including histone 
acetylases and arginine methyltransferases, co-associate with most nuclear receptors in the 
context of local chromatin [28]. The finding that sirtuins directly regulate nuclear hormone 
receptors provides a new mechanism by which nuclear receptors might coordinate metabolic 
signaling. Local metabolic changes in NAD
+
;NADH ratios sensed by the sirtuins might, in 
turn, regulate local activity of nuclear receptors. As nuclear receptors are located in distinct 
subcellular compartments, including the cellular membrane, mitochondria, cytoplasm and 
nucleus, and distinct sirtuins occupy discrete subcellular compartments, it will be of interest to 
determine the role of the sirtuins on nuclear receptor activity in these distinct subcellular 
locales. The finding that SIRT1 regulates the nuclear receptor co-integrator p300 provides a 
new mechanism by which local NAD
+
:NADH changes might coordinate nuclear receptor 
function within the cell.  
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Figures and Tables 
 
Figure 1 
Domain architecture of human sirtuin family of Class III NAD+-dependent histone 
deacetylases Schematics represent the domain structure of human sirtuins. Amino acid 
positions are noted above each schematic. The domains are represented in different colors. 
SIRT1 is not drawn to the same scale as the other sirtuins. Adapted from UniProt Universal 
Protein Resource Database. 
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Figure 2 
Proteins involved in ligand-induced hormone signaling are acetylated nuclear receptor 
ligands that induce multiple downstream molecular interactions. Proteins known to be 
involved in nuclear receptor signaling are shown. Proteins with an asterisk have been shown 
to serve as substrates for acetylation in vitro both within the cytosol and in the nucleus.  
 
 
 
 
 
  
Figure 3  
Transcriptional regulation of the androgen receptor through epigenetic modifications. 
Acetylation and subsequent activation of the androgen receptor is mediated by p300 and 
P/CAF at the indicated Lys residues. The AR is also capable of being methylated by CARM1 
and phosphorylated by MAPK, PKC or PKA at multiple serine residues. The exact location of 
such residues remains a controversial area of research. Because these modifications are 
mutually exclusive, but can occur on the same residues, the possibility of ‘crosstalk’ between 
modifications is suggested. Deacetylation and, therefore, transcriptional repression is elicited 
by SIRT1. Also shown within the figure insert is the interaction between histone 
acetyltransferases P/CAF and p300 as they associate with H4K16.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Table 1 
The functions, interactions and subcellular location of the mammalian sirtuins
a 
 
a
 Adapted from Refs [35, 74]. 
